Online inquiry

IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12234MR)

This product GTTS-WQ12234MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12234MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4950MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ15137MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ12419MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ949MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
GTTS-WQ10945MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MBG-453
GTTS-WQ7069MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ7425MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ3929MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-145
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW